問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberSHR-1210-III-310
Active

2019-11-01 - 2025-02-28

Phase III

Terminated8

  • Trial Applicant

    IQVIA RDS Taiwan Ltd.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator 蘇維文 Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chia-Jui Yen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 洪肇宏 Division of General Internal Medicine

Co-Principal Investigator

  • 張德生 Division of General Internal Medicine
  • 陳慰明 Division of General Internal Medicine
  • 陳奕行 Division of General Internal Medicine
  • 沈建亨 Division of General Internal Medicine
  • 許晃維 Division of General Internal Medicine
  • 盧勝男 Division of General Internal Medicine
  • 官鋒澤 Division of Hematology & Oncology
  • 許勝榮 Division of Radiology
  • 顏志維 Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chiun Hsu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Yee Chao Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Tsai-Sheng Yang Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 饒坤銘 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 陳彥豪 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    40 participants

  • Global

    510 participants